Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/1297
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Prince, Miles | - |
dc.contributor.other | Gautam, Ashish | - |
dc.contributor.other | Kim, Youn | - |
dc.date.accessioned | 2018-05-11T03:03:47Z | - |
dc.date.available | 2018-05-11T03:03:47Z | - |
dc.date.issued | 2018-02 | - |
dc.identifier.citation | Oncotarget. 2018 Feb 10;9(15):11887-11888 | en_US |
dc.identifier.issn | 1949-2553 | en_US |
dc.identifier.uri | http://hdl.handle.net/11434/1297 | - |
dc.description.abstract | Editorial | en_US |
dc.publisher | Impact Journals | en_US |
dc.relation.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844715/ | en_US |
dc.subject | ALCANZA Study | en_US |
dc.subject | Cutaneous T-Cell Lymphoma | en_US |
dc.subject | CTCL | en_US |
dc.subject | Anti-CD30 | en_US |
dc.subject | Brentuximab Vedotin | en_US |
dc.subject | Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia | en_US |
dc.title | Brentuximab vedotin: targeting CD30 as standard in CTCL. | en_US |
dc.type | Letter | en_US |
dc.rights.holder | 2018 Prince et al. | en_US |
dc.identifier.doi | 10.18632/oncotarget.24472 | en_US |
dc.identifier.journaltitle | Oncotarget | en_US |
dc.description.pubmeduri | https://www.ncbi.nlm.nih.gov/pubmed/29552279 | en_US |
dc.description.affiliates | Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum | en_US |
dc.description.affiliates | The University of Melbourne, VIC, Australia | en_US |
dc.type.contenttype | Text | en_US |
Appears in Collections: | Cancer Services |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Prince et al 2018.pdf | 662.04 kB | Adobe PDF | View/Open |
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.